Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Russell Lewis, Jan Philipp Bewersdorf & Amer M Zeidan. (2021) Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Management and Research 13, pages 645-657.
Read now
Read now
Nora Chokr, Alexander B. Pine, Jan Philipp Bewersdorf, Rory M. Shallis, Maximilian Stahl & Amer M. Zeidan. (2019) Getting personal with myelodysplastic syndromes: is now the right time?. Expert Review of Hematology 12:4, pages 215-224.
Read now
Read now
Rory M. Shallis, Nora Chokr, Maximilian Stahl, Alexander B. Pine & Amer M. Zeidan. (2018) Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review of Hematology 11:9, pages 715-726.
Read now
Read now
Rory M. Shallis & Amer M. Zeidan. (2018) Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?. Leukemia & Lymphoma 59:9, pages 2015-2017.
Read now
Read now
Amer M. Zeidan, Maximilian Stahl & Rami Komrokji. (2016) Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion on Emerging Drugs 21:3, pages 283-300.
Read now
Read now
Articles from other publishers (9)
Heike Weidner, Ulrike Baschant, Franziska Lademann, Maria G. Ledesma Colunga, Ekaterina Balaian, Christine Hofbauer, Barbara M. Misof, Paul Roschger, Stéphane Blouin, William G. Richards, Uwe Platzbecker, Lorenz C. Hofbauer & Martina Rauner. (2020) Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. JCI Insight 5:15.
Crossref
Crossref
Jan Philipp Bewersdorf & Amer M. Zeidan. 2020. Diagnosis and Management of Myelodysplastic Syndromes. Diagnosis and Management of Myelodysplastic Syndromes
109
127
.
Amer M. Zeidan, Rory M. Shallis, Rong Wang, Amy Davidoff & Xiaomei Ma. (2019) Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 34, pages 1-15.
Crossref
Crossref
Amer M. Zeidan, Smith Giri, Michelle DeVeaux, Samir K. Ballas & Vu H. Duong. (2018) Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Annals of Hematology 98:2, pages 339-350.
Crossref
Crossref
Rory M. Shallis & Amer M. Zeidan. (2018) More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 18:1.
Crossref
Crossref
Rory M. Shallis, Mina L. Xu, Nikolai A. Podoltsev, Susanna A. Curtis, Bryden T. Considine, Suchin R. Khanna, Alexa J. Siddon & Amer M. Zeidan. (2018) Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals of Hematology 97:12, pages 2333-2343.
Crossref
Crossref
Rory M. Shallis, Rami Ahmad & Amer M. Zeidan. (2018) The genetic and molecular pathogenesis of myelodysplastic syndromes. European Journal of Haematology 101:3, pages 260-271.
Crossref
Crossref
A M Zeidan, N Al Ali, J Barnard, E Padron, J E Lancet, M A Sekeres, D P Steensma, A DeZern, G Roboz, E Jabbour, G Garcia-Manero, A List & R Komrokji. (2017) Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 31:6, pages 1391-1397.
Crossref
Crossref
Amer M. Zeidan, B. Douglas Smith, Hetty E. Carraway, Ivana Gojo, Amy DeZern & Steven D. Gore. (2017) A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. British Journal of Haematology 176:2, pages 241-247.
Crossref
Crossref